Formulation

Abstract

A formulation, a method of making said formulation, as well as containers and systems including and using said formulation. In particular, the formulation includes one or more cannabinoids, one or more stabilizing component and one or more carrier constituents, wherein the total amount of the one or more carrier constituents is 50% w/w or more based on the total weight of the formulation, wherein said formulation has a pH of less than about 7.5.

1 . A formulation comprising: one or more cannabinoids, one or more stabilizing component and one or more carrier constituents, wherein the total amount of the one or more carrier constituents is 50% w/w or more based on the total weight of the formulation, wherein said formulation has a pH of less than about 7.5. 
     
     
         2 . The formulation according to  claim 1 , wherein the cannabinoids are selected from cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), Tetrahydrocannabinol (THC), including its isomers Δ 6a,10a -Tetrahydrocannabinol (Δ 6a,10a -THC), Δ 6a(7) -Tetrahydrocannabinol (Δ 6a(7) -THC), Δ 8 -tetrahydrocannabinol (Δ 8 -THC), Δ 9 -tetrahydrocannabinol (Δ 9 -THC), Δ 10 -tetrahydrocannabinol (Δ 10 -THC), Δ 9,11 -tetrahydrocannabinol (Δ 9,11 -THC), cannabinol (CBN) and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabmolic acid (THCA), and tetrahydrocannabivarinic acid (THCV A). 
     
     
         3 . The formulation according to  claim 2 , wherein the cannabinoids are selected from cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), Δ 6a,10a -Tetrahydrocannabinol (Δ 6a,10a -THC), Δ 6a(7) -Tetrahydrocannabinol (Δ 6a(7) -THC), Δ 8 -tetrahydrocannabinol (Δ 8 -THC), Δ 9 -tetrahydrocannabinol (Δ 9 -THC), Δ 10 -tetrahydrocannabinol (Δ 10 -THC), Δ 9,11 -tetrahydrocannabinol (Δ 9,11 -THC) and cannabinol (CBN). 
     
     
         4 . The formulation according to  claim 2 , wherein the cannabinoids are selected from cannabidiol (CBD), Δ 9 -tetrahydrocannabinol (Δ 9 -THC), and cannabinol (CBN). 
     
     
         5 . The formulation according to  claim 2 , wherein the cannabinoids comprise cannabidiol (CBD). 
     
     
         6 . The formulation according to  claim 1 , wherein the cannabinoid is cannabidiol. 
     
     
         7 . The formulation according to  claim 1 , wherein the cannabinoids comprise cannabidiol (CBD) and one or more cannabinoids selected from cannabigerol (CBG), cannabichromene (CBC), cannabidiol (CBD), Tetrahydrocannabinol (THC), including its isomers Δ 6a,10a -Tetrahydrocannabinol (Δ 6a,10a -THC), Δ 6a(7) -Tetrahydrocannabinol (Δ 6a(7) -THC), Δ 8 -tetrahydrocannabinol (Δ 8 -THC), Δ 9 -tetrahydrocannabinol (Δ 9 -THC), Δ 10 -tetrahydrocannabinol (Δ 10 -THC), Δ 9,11 -tetrahydrocannabinol (Δ 9,11 -THC), cannabinol (CBN) and cannabinodiol (CBDL), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), cannabinerolic acid, cannabidiolic acid (CBDA), Cannabinol propyl variant (CBNV), cannabitriol (CBO), tetrahydrocannabmolic acid (THCA), and tetrahydrocannabivarinic acid (THCV A). 
     
     
         8 . The formulation according to  claim 7 , wherein the cannabinoids comprise cannabidiol (CBD) and one or more cannabinoids selected from cannabigerol (CBG), cannabichromene (CBC), Δ 6a,10a -Tetrahydrocannabinol (Δ 6a,10a -THC), Δ 6a(7) -Tetrahydrocannabinol (Δ 6a(7) -THC), Δ 8 -tetrahydrocannabinol (Δ 8 -THC), Δ 9 -tetrahydrocannabinol (Δ 9 -THC), Δ 10 -tetrahydrocannabinol (Δ 10 -THC), Δ 9,11 -tetrahydrocannabinol (Δ 9,11 -THC) and cannabinol (CBN). 
     
     
         9 . The formulation according to  claim 7 , wherein the cannabinoids comprise cannabidiol (CBD) and one or more cannabinoids selected from Δ 9 -tetrahydrocannabinol (Δ 9 -THC) and cannabinol (CBN). 
     
     
         10 . The formulation according to  claim 1 , wherein the one or more stabilizing components are selected from antioxidants, pH modulators, chelators and radical scavengers, and combinations thereof. 
     
     
         11 . The formulation according to  claim 10 , wherein the one or more stabilizing components are one or more antioxidants and one or more chelators. 
     
     
         12 . The formulation according to  claim 10 , wherein the one or more antioxidants are selected from the enediol class of compounds. 
     
     
         13 . The formulation according to  claim 1 , wherein the one or more stabilizing components are selected from the group consisting of ascorbic acid, sodium ascorbate, ethyl maltol, thymol, maltol, pyruvic acid, lactic acid, carvacrol, alpha-keto glutaric acid, alpha-keto glutarate salt, triethyl citrate, ethyl vanillate, quercetin, sucrose acetate isobutyrate, retinol, cholecalciferol, vitamin K-hydroquinone, citric acid, tartaric acid, ferulic acid, courmaric acid, propyl gallate, gallic acid, alpha lipoic acid, ascorbyl palmitate, lutein, lycopene, resveratrol, rutin, catechin, carnosol, rosmarinic acid, lipoic acid, α-resorcylic, pyrogallol, malvidin, theaflavin, apigenin, eriodictyol, glycitein, chrysoeriol, kaempferol, luteolin, vitexin, isovitexin, orientin, cannflavin A, cannflavin B, cannflavin C, delphinidin, pelargonidin, epicatechin, myricetin, chrysin, naringenin, α-terpineol, nerol, geranyl acetate, fenchol, propyl gallate, tert-butylhydroquinone, carvone and combinations thereof. 
     
     
         14 . The formulation according to  claim 13 , wherein the one or more stabilizing components are selected from one or more of ascorbic acid and sodium ascorbate. 
     
     
         15 . The formulation according to  claim 14 , wherein the stabilizing components are ascorbic acid and sodium ascorbate. 
     
     
         16 . The formulation according to  claim 1 , wherein the one or more stabilizing components are each present in an amount of at least 500 ppm. 
     
     
         17 . The formulation according to  claim 1 , wherein the one or more stabilizing components are each present in an amount of at least 1000 ppm. 
     
     
         18 . The formulation according to  claim 17 , wherein the one or more stabilizing components are each present in an amount of at least 1500 ppm. 
     
     
         19 . The formulation according to  claim 18 , wherein the one or more stabilizing components are each present in an amount of at least 2000 ppm. 
     
     
         20 . The formulation according to  claim 1 , wherein the formulation has a pH of from about 6 to about 7. 
     
     
         21 . The formulation according to  claim 20 , wherein the formulation has a pH of from about 6.5 to about 7. 
     
     
         22 . The formulation according to  claim 20 , wherein the formulation has a pH of from about 6 to about 6.5. 
     
     
         23 . The formulation according to  claim 1 , wherein the carrier constituent comprises one or more of glycerol, propylene glycol, triethylene glycol, tetraethylene glycol, 1,3-butylene glycol, erythritol, meso-Erythritol, ethyl laurate, a diethyl suberate, triethylene glycol diacetate, triacetin, a diacetin mixture, benzyl benzoate, benzyl phenyl acetate, tributyrin, lauryl acetate, lauric acid, myristic acid, and propylene carbonate. 
     
     
         24 . The formulation according to  claim 23 , wherein the total amount of carrier constituents is 60% w/w or more based on the total weight of the formulation. 
     
     
         25 . The formulation according to  claim 23 , wherein the total amount of carrier constituents is 70% w/w or more based on the total weight of the formulation. 
     
     
         26 . The formulation according to  claim 1 , wherein the carrier constituent comprises propylene glycol. 
     
     
         27 . The formulation according to  claim 26 , wherein propylene glycol is present in an amount of at least 50% w/w based on the total weight of the formulation. 
     
     
         28 . The formulation according to  claim 26 , wherein propylene glycol is present in an amount of at least 60% w/w based on the total weight of the formulation. 
     
     
         29 . The formulation according to  claim 26 , wherein propylene glycol is present in an amount of at least 70% w/w based on the total weight of the formulation. 
     
     
         30 . The formulation according to  claim 1 , wherein the carrier constituent comprises glycerol. 
     
     
         31 . The formulation according to  claim 29 , wherein glycerol is present in an amount of at least 50% w/w based on the total weight of the formulation. 
     
     
         32 . The formulation according to  claim 30 , wherein glycerol is present in an amount of at least 60% w/w based on the total weight of the formulation. 
     
     
         33 . The formulation according to  claim 30 , wherein glycerol is present in an amount of at least 70% w/w based on the total weight of the formulation. 
     
     
         34 . The formulation according to  claim 26 , wherein both glycerol and propylene glycol are present as carrier constituents. 
     
     
         35 . The formulation according to  claim 34 , wherein the formulation comprises:
 60 to 90% w/w propylene glycol and 40 to 10% w/w glycerol based on the total amount of propylene glycol and glycerol in the formulation.   
     
     
         36 . The formulation according to  claim 34 , wherein the formulation comprises 70 to 80% w/w propylene glycol and 30 to 20% w/w glycerol based on the total amount of propylene glycol and glycerol in the formulation. 
     
     
         37 . The formulation according to  claim 34 , wherein the formulation comprises about 70% w/w propylene glycol and about 30% w/w glycerol based on the total amount of propylene glycol and glycerol in the formulation. 
     
     
         38 . The formulation according to  claim 1 , wherein at least one cannabinoid is present in the formulation in an amount of 5 mg/ml or more. 
     
     
         39 . The formulation according to  claim 38 , wherein at least one cannabinoid is present in the formulation in an amount of 10 mg/ml or more. 
     
     
         40 . The formulation according to  claim 38 , wherein at least one cannabinoid is present in the formulation in an amount of 30 mg/ml or more. 
     
     
         41 . The formulation according to  claim 38 , wherein at least one cannabinoid is present in the formulation in an amount of 60 mg/ml or more. 
     
     
         42 . The formulation according to  claim 1 , wherein the formulation additionally comprises one or more terpenes selected from pinene (alpha and beta), geraniol, linalool, limonene, eucalyptol, menthone, iso-menthone, piperitone, beta-bourbonene, germacrene and myrcene and mixtures thereof. 
     
     
         43 . The formulation according to  claim 42 , wherein the total amount of terpene present in the formulation is up to about 10 mg/ml. 
     
     
         44 . The formulation according to  claim 1 , wherein the formulation further comprises one or more active constituents in addition to the cannabinoid. 
     
     
         45 . The formulation according to  claim 44 , wherein the one or more active constituents is an olfactory active constituent. 
     
     
         46 . The formulation according to  claim 1 , wherein the formulation takes the form of a liquid at about 25° C. 
     
     
         47 . The formulation according to  claim 1 , wherein the content of one or more specific cannabinoids is at least 80% of the initial content of the one or more specific cannabinoids based on a mg/ml basis of the formulation after 4 weeks at 40° C. and 75% Relative Humidity. 
     
     
         48 . A packaged formulation comprising a formulation according  claim 1  and wherein the packaged formulation is impermeable to air. 
     
     
         49 . A method of producing a formulation according to  claim 1 , wherein the method comprises combining each of the one or more cannabinoids, one or more stabilizing components and one or more carrier constituents so as to form the formulation, wherein the one or more stabilizing components and one or more carrier constituents are combined to form a first mixture, and then the one or more cannabinoids is added to the first mixture to produce the formulation. 
     
     
         50 . A method of preparing a packaged formulation, wherein the method comprises packaging a formulation according to  claim 1  in a container, wherein the container further comprises a volume of gas no greater than 20% of the total volume of the container. 
     
     
         51 . A container comprising a formulation according to  claim 1 , wherein the container further comprises a volume of gas no greater than 20% of the total volume of the container. 
     
     
         52 . A container according to  claim 51 , wherein the gas is argon.